Peninsula drugmaker divests biosimilar eye drug for $170M cash

The drug, a lookalike version of Genentech's Lucentis for wet age-related macular degeneration and other eye conditions, was licensed in 2019 by Coherus.

Source: bizjournals.com Health Care:Biotechnology headlines - January 22, 2024 Category: Biotechnology Authors: Ron Leuty Source Type: news